These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36082509)

  • 1. Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics.
    Richaud AD; Zaghouani M; Zhao G; Wangpaichitr M; Savaraj N; Roche SP
    Chembiochem; 2022 Nov; 23(21):e202200449. PubMed ID: 36082509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?
    Ponce LF; García-Martínez K; León K; Valiente PA
    Proteins; 2021 Feb; 89(2):141-148. PubMed ID: 32862461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
    Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
    MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
    Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
    Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1.
    Wang S; Khan FI
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
    Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
    Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling a Conserved Conformation of the FG Loop upon the Binding of Natural Ligands to the Human and Murine PD1.
    Ponce LF; Leon K; Valiente PA
    J Phys Chem B; 2022 Feb; 126(7):1441-1446. PubMed ID: 35167293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
    Fromm G; de Silva S; Johannes K; Patel A; Hornblower JC; Schreiber TH
    J Immunother Cancer; 2018 Dec; 6(1):149. PubMed ID: 30563566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab.
    Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL
    Phys Chem Chem Phys; 2021 Sep; 23(37):21207-21217. PubMed ID: 34533552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
    Park UB; Jeong TJ; Gu N; Lee HT; Heo YS
    Biochem Biophys Res Commun; 2022 Apr; 599():31-37. PubMed ID: 35168061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
    Jiang K; Zou H
    Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.
    Ameli F; Shajareh E; Mokhtari M; Kosari F
    BMC Cancer; 2022 Aug; 22(1):848. PubMed ID: 35922773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
    Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
    Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
    Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
    Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD1/PDL1 induced psoriasis.
    Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
    Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.